Overview
- A Nature Communications paper published on Friday, Oct. 2, 2026, reports that researchers at Northwestern traced acute, cannabinoid-driven anxiety in mice to a small group of somatostatin-expressing neurons in the central amygdala.
- The team used a potent synthetic cannabinoid (CP55940), predator-odor exposure and head-mounted miniscopes to show dose- and context-dependent increases in freezing and avoidance tied to real-time activation of those somatostatin (SOM) cells.
- Ex vivo electrophysiology indicated cannabinoids suppress local GABAergic input—the brain’s inhibitory “brake”—onto CeA SOM neurons, and chemogenetic or genetic silencing of those neurons abolished the drug-driven threat avoidance.
- The findings provide a clear cellular mechanism for why a pleasant cannabis experience can flip to panic when doses are high or the environment is stressful and they nominate CeA SOM neurons as a potential therapeutic target.
- Key caveats are that the work used a strong synthetic agonist in mice, so human relevance and clinical treatments are unproven; however, the results come as high-potency cannabis products and related emergency visits have risen, which could shape future clinical research and harm-reduction strategies.